Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ObsEva SA
The study is a prospective, randomized, parallel group, double-blind, placebo-controlled phase 3 study investigating the efficacy and safety of OBE2109 alone and in combination with add-back therapy for the treatment of uterine fibroids.
Subjects will be randomized to one of 5 treatment groups in a 1:1:1:1:1 ratio.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Premenopausal woman at screening.
Body Mass Index ≥ 18 kg/m2.
Menstrual cycles ≥ 21 days and ≤ 40 days.
Presence of uterine fibroids.
Heavy menstrual blood loss for each of the 2 menstrual periods assessed at screening using the alkaline hematin method.
You may not be if
The subject is pregnant or breast-feeding or is planning a pregnancy within the duration of the treatment period of the study.
History of uterus surgery that would interfere with the study.
The subject's condition is so severe that she will require surgery within 6 months regardless of the treatment provided.
Undiagnosed abnormal uterine bleeding.
Significant risk of osteoporosis or history of, or known osteoporosis or other metabolic bone disease.